BD Surgiphor™ Surgical Wound Irrigation System Expands to Europe to Help Hospitals Improve Patient Safety

Rhea-AI Summary

BD (NYSE: BDX) announced the European launch of the BD Surgiphor Surgical Wound Irrigation System on November 24, 2025. The device received CE approval and is now available in select European countries. Surgiphor is a sterile, pre-mixed, ready-to-use irrigation solution that uses a trusted antiseptic preservative to help loosen and remove debris and reduce bacterial load in surgical wounds. BD says the product is designed to simplify wound irrigation, reduce preparation time, and support evidence-based practices to help lower the risk of surgical site infections and improve surgical safety.

Availability is limited to select countries in Europe; healthcare providers should contact BD sales representatives for regional access and product details.

Positive

• CE approval obtained for Surgiphor
• Product is sterile, pre-mixed and ready to use
• Antiseptic preservative included to reduce bacterial load
• Designed to reduce preparation time and simplify irrigation

Negative

• Availability limited to select European countries

News Market Reaction

-0.91%

1 alert

-0.91% News Effect

On the day this news was published, BDX declined 0.91%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

FRANKLIN LAKES, N.J., Nov. 24, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Surgiphor™ Surgical Wound Irrigation System in Europe. The system is the first of its kind to receive Conformité Européenne (CE) approval and is now available in select European countries.

BD Surgiphor™ is a sterile, ready-to-use irrigation solution designed to help loosen and remove debris from surgical wounds during procedures. By flushing out debris and foreign materials, including microorganisms, it helps reduce the bacterial load that could lead to infection — a key factor associated with surgical site infections^*1.

"This European launch marks a significant milestone in advancing surgical care," said Rian Seger, worldwide president of BD Surgery. "Surgical Site Infections are multifactorial and continue to present serious challenges to both patient outcomes and healthcare systems. Surgiphor™ supports clinicians in implementing evidence-based practices — such as surgical wound irrigation — to help reduce risk, enhance recovery, and improve overall surgical safety."

What makes Surgiphor™ different:

• It's pre-mixed and sterile, so hospitals don't need to prepare it before surgery¹.
• It uses a trusted antiseptic as preservative in the solution to help reduce bacterial load that could lead to infection^*1.
• The easy-to-handle design allows surgical teams to apply it quickly and precisely¹.

By simplifying surgical wound irrigation and reducing preparation time, Surgiphor™ helps hospitals operate more efficiently while supporting safer outcomes for patients¹. This launch reflects BD's ongoing commitment to advancing surgical care through practical, proven solutions that put patient safety first. For more information, contact your BD sales rep.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiency, improve safety, and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

^{* Surgical wound was in a simulated animal model}

References: 1. BD data on file. Data generated in a preclinical model.

Contacts:
Media:	Investors:
Fallon McLoughlin	Adam Reiffe
Director, Public Relations	VP, Investor Relations
201.258.0361	201.847.6927
fallon.mcloughlin@bd.com	adam.reiffe@bd.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-surgiphor-surgical-wound-irrigation-system-expands-to-europe-to-help-hospitals-improve-patient-safety-302624084.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

What did BD (BDX) announce on November 24, 2025 about Surgiphor in Europe?

BD announced the European launch of BD Surgiphor, which received CE approval and is available in select European countries.

How does BD Surgiphor claim to reduce surgical site infection risk for BD (BDX)?

Surgiphor is a sterile, pre-mixed irrigation solution that uses a trusted antiseptic preservative to help remove debris and reduce bacterial load.

Where can hospitals in Europe obtain BD Surgiphor (BDX) and when is it available?

The product is available now in select European countries; hospitals should contact their BD sales representative for regional availability.

What are the operational benefits BD (BDX) highlights for Surgiphor?

BD says Surgiphor simplifies wound irrigation and reduces preparation time, helping surgical teams apply irrigation quickly and precisely.

Does BD (BDX) claim clinical trial results for Surgiphor in the November 24, 2025 announcement?

The announcement references use to help reduce bacterial load and support evidence-based practices but does not present specific clinical trial results or quantified outcomes.